• Je něco špatně v tomto záznamu ?

Metabolomic and lipidomic changes triggered by lipopolysaccharide-induced systemic inflammation in transgenic APdE9 mice

E. Puris, Š. Kouřil, L. Najdekr, S. Loppi, P. Korhonen, KM. Kanninen, T. Malm, J. Koistinaho, D. Friedecký, M. Gynther

. 2021 ; 11 (1) : 13076. [pub] 20210622

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004198

Peripheral infections followed by systemic inflammation may contribute to the onset of Alzheimer`s disease (AD) and accelerate the disease progression later in life. Yet, the impact of systemic inflammation on the plasma and brain tissue metabolome and lipidome in AD has not been investigated. In this study, targeted metabolomic and untargeted lipidomic profiling experiments were performed on the plasma, cortices, and hippocampi of wild-type (WT) mice and transgenic APdE9 mice after chronic lipopolysaccharide (LPS) treatment, as well as saline-treated APdE9 mice. The lipidome and the metabolome of these mice were compared to saline-treated WT animals. In the brain tissue of all three models, the lipidome was more influenced than the metabolome. The LPS-treated APdE9 mice had the highest number of changes in brain metabolic pathways with significant alterations in levels of lysine, myo-inositol, spermine, phosphocreatine, acylcarnitines and diacylglycerols, which were not observed in the saline-treated APdE9 mice. In the WT mice, the effect of the LPS administration on metabolome and lipidome was negligible. The study provided exciting information about the biochemical perturbations due to LPS-induced inflammation in the transgenic AD model, which can significantly enhance our understanding of the role of systemic inflammation in AD pathogenesis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004198
003      
CZ-PrNML
005      
20240125121330.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-021-92602-4 $2 doi
035    __
$a (PubMed)34158563
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Puris, Elena $u School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland. elena.puris@uni-heidelberg.de $u Institute of Pharmacy and Molecular Biotechnology, Ruprecht-Karls-University, Im Neuenheimer Feld 329, 69120, Heidelberg, Germany. elena.puris@uni-heidelberg.de
245    10
$a Metabolomic and lipidomic changes triggered by lipopolysaccharide-induced systemic inflammation in transgenic APdE9 mice / $c E. Puris, Š. Kouřil, L. Najdekr, S. Loppi, P. Korhonen, KM. Kanninen, T. Malm, J. Koistinaho, D. Friedecký, M. Gynther
520    9_
$a Peripheral infections followed by systemic inflammation may contribute to the onset of Alzheimer`s disease (AD) and accelerate the disease progression later in life. Yet, the impact of systemic inflammation on the plasma and brain tissue metabolome and lipidome in AD has not been investigated. In this study, targeted metabolomic and untargeted lipidomic profiling experiments were performed on the plasma, cortices, and hippocampi of wild-type (WT) mice and transgenic APdE9 mice after chronic lipopolysaccharide (LPS) treatment, as well as saline-treated APdE9 mice. The lipidome and the metabolome of these mice were compared to saline-treated WT animals. In the brain tissue of all three models, the lipidome was more influenced than the metabolome. The LPS-treated APdE9 mice had the highest number of changes in brain metabolic pathways with significant alterations in levels of lysine, myo-inositol, spermine, phosphocreatine, acylcarnitines and diacylglycerols, which were not observed in the saline-treated APdE9 mice. In the WT mice, the effect of the LPS administration on metabolome and lipidome was negligible. The study provided exciting information about the biochemical perturbations due to LPS-induced inflammation in the transgenic AD model, which can significantly enhance our understanding of the role of systemic inflammation in AD pathogenesis.
650    _2
$a Alzheimerova nemoc $x metabolismus $7 D000544
650    _2
$a amyloidní beta-protein $x metabolismus $7 D016229
650    _2
$a amyloidový prekurzorový protein beta $x genetika $x imunologie $x metabolismus $7 D016564
650    _2
$a zvířata $7 D000818
650    _2
$a mozek $x metabolismus $7 D001921
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hipokampus $x metabolismus $7 D006624
650    _2
$a zánět $x metabolismus $7 D007249
650    _2
$a lipidomika $x metody $7 D000081362
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metabolom $7 D055442
650    _2
$a metabolomika $x metody $7 D055432
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši transgenní $7 D008822
650    _2
$a presenilin-1 $x metabolismus $7 D053764
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kouřil, Štěpán $u Institute of Molecular and Translational Medicine, Palacký University Olomouc, Hněvotínská 5, 77900, Olomouc, Czech Republic $u Department of Clinical Biochemistry, University Hospital Olomouc, I.P. Pavlova 6, 77900, Olomouc, Czech Republic $7 xx0313061
700    1_
$a Najdekr, Lukáš $u Institute of Molecular and Translational Medicine, Palacký University Olomouc, Hněvotínská 5, 77900, Olomouc, Czech Republic
700    1_
$a Loppi, Sanna $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland $u Department of Immunobiology, University of Arizona, 1656 E Mabel Street, Tucson, AZ, 85724-5221, USA
700    1_
$a Korhonen, Paula $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
700    1_
$a Kanninen, Katja M $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
700    1_
$a Malm, Tarja $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
700    1_
$a Koistinaho, Jari $u A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland $u Neuroscience Center, Helsinki Institute for Life Science, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland
700    1_
$a Friedecký, David $u Institute of Molecular and Translational Medicine, Palacký University Olomouc, Hněvotínská 5, 77900, Olomouc, Czech Republic $u Department of Clinical Biochemistry, University Hospital Olomouc, I.P. Pavlova 6, 77900, Olomouc, Czech Republic
700    1_
$a Gynther, Mikko $u School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 11, č. 1 (2021), s. 13076
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34158563 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20240125121325 $b ABA008
999    __
$a ok $b bmc $g 1751605 $s 1155347
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 1 $d 13076 $e 20210622 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace